Early access
Sign in
Taking people in GermanyPhase 1

Safety and body processing of ANB033 in adults with eosinophilic esophagitis or celiac disease

Tests how safe ANB033 is and how the body handles it in adults.

Key facts

Who runs it
First Tracks Biotherapeutics Inc.
Where
Erlangen, Hamburg, Leipzig, Mainz, and Munich, GermanySee the 5 sitesAlso in 6 other countries, 14 sites
Registry title
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033
Status
Recruiting
Phase
Phase 1
People taking part
48 people, planned
Started
14 Nov 2025
Expected to end
31 Dec 2026
Type of study
Interventional
Record updated
2 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults to test single and multiple doses of ANB033. It is linked to eosinophilic esophagitis (EoE) and celiac disease, and healthy volunteers can join.

Age
18 years and older
Sex
All sexes

Where in Germany

Also in 6 other countries, 14 sites

  • Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
  • University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
  • Universitaet LeipzigLeipzig, GermanyTaking people
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, GermanyTaking people
  • Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)Munich, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Safety and body processing of ANB033 in adults with eosinophilic esophagitis or celiac diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
2 October 2026